Palisade Bio closes $13.8M underwritten public offering of common stock, Series B preferred, and warrants

PALISADE BIO, INC.

Gross proceeds ~$13.8M; net proceeds ~$12.2M after underwriting discounts and estimated expenses.
Issued 49.36M shares common, 1,460 shares Series B preferred (convertible into 4,000 common each), plus warrants for 55.2M shares at $0.25 exercise price.
Underwriter's over-allotment option fully exercised for an additional 7.2M common shares and warrants.
Warrants exercisable only after stockholder approval per Nasdaq rules; Series 1 expires in 1 year, Series 2 in 5 years.
Post-offering outstanding common shares: 71,240,169 (excluding 5.84M shares from Series B conversion).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.